This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Breast Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The aim of this study is to evaluate the potential of a Lapatinib plus Caelyx combination therapy as an effective and safe therapeutic regimen with a favourable cardiotoxicity profile, in the treatment of metastatic breast cancer following failure of prior trastuzumab.

Provided treatments

  • Drug: doxorubicinhydrochloride, Lapatinib
Tris trial is registered with FDA with number: NCT00903656. The sponsor of the trial is Arbeitsgemeinschaft medikamentoese Tumortherapie and it is looking for 24 volunteers for the current phase.
Official trial title:
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study